Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Bexion Partners with Molecular Targeting Technologies on Novel Cancer Imaging Agent
May 7th, 2008
Molecular Targeting Technologies, Inc. (MTTI) announced that they have agreed to collaborate with Bexion Pharmaceuticals, LLC (Bexion) to develop a novel nanovesicle for molecular imaging of tumors. Bexion has demonstrated that specific versions of these nanovesicles can be used to selectively target a broad range of tumors (both solid and hematologic). Specific formulations have also demonstrated the potential for treatment of a wide range of human cancers, including gliomas, prostate and pancreatic cancer. "This novel nanovesicle technology will dramatically augment our ability to accurately diagnose and provide timely cancer treatment. Our initial...
Source: Vaccine Weekly (2008-05-07)
|
